A therapy-resistant chronic leg ulcer treated successfully with topical basic fibroblast growth factor.
We report a patient with rheumatoid arthritis who had a chronic leg ulcer with long-standing resistance to therapy. Topical basic fibroblast growth factor (bFGF) at a dose of 30 micrograms/day for 3 months was clinically effective in reducing the ulcer area by promoting angiogenesis, re-epithelization, granulation and scar formation. bFGF may be an effective treatment for therapy-resistant leg ulcers.
Kurokawa
I
I
Department of Dermatology, Hyogo Prefectural Tsukaguchi Hospital, Hyogo, Japan. ikuro@alles.or.jp
Hayami
J
J
Kita
Y
Y
D000287:Administration, Topical; D000328:Adult; D001172:Arthritis, Rheumatoid / Q000150:complications; D002908:Chronic Disease; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage*; D006801:Humans; D007871:Leg Ulcer / Q000150:complications / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D017211:Treatment Failure; D016896:Treatment Outcome
D016222:Fibroblast Growth Factor 2